ST.
PAUL, Minn., Aug. 27,
2024 /PRNewswire/ -- ScaleReady™, in collaboration
with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ:
TECH) and CellReady™, today announced that Dr. Steve Feldman, Scientific Director and Site Head
of Stanford Medicine's Laboratory
for Cell and Gene Medicine (LCGM),
has been awarded the inaugural G-Rex® Grant. Dr. Feldman's
$300,000 G-Rex Grant will enable
expeditious development of Stanford
Medicine's LCGM's G-Rex platform for CAR-T cell therapy
manufacturing, which will be offered to internal investigators and
external developers who are seeking its development and
manufacturing services.
"Stanford's LCGM anticipates a need to support a greater number
of clinical trials and the G-Rex Grant will be used to help meet
that need," said Dr. Feldman.
"We are honored to award the inaugural G-Rex Grant to Dr.
Feldman and his team at Stanford Medicine LCGM. Stanford University is a world-class institution
with faculty who have a reputation for innovative and
ground-breaking achievements. Their work aligns with Wilson Wolf's mission of bringing hope to cancer
patients, one G-Rex at a time" said John
Wilson, CEO of Wilson Wolf
and co-inventor of G-Rex.
As part of the G-Rex Grant, Stanford Medicine LCGM will deploy
their G-Rex-centric manufacturing process in an upcoming Phase 1
trial for GPC2+ pediatric neuroblastoma and
medulloblastoma. Previously, the FDA had recommended sponsors
develop and implement potency assays earlier in the clinical trial
process. With that objective, Stanford Medicine LCGM plans to
implement Bio-Techne's leading automated multiplexing immunoassay
platform, Ella™, as a potency assay for final drug product
release.
Furthermore, Stanford Medicine LCGM will collaborate with
CellReady, the world's first and only G-Rex based contract
development and manufacturing organization (CDMO), to leverage
their proven capacity to quickly create G-Rex master batch records
that establish manufacturing simplicity, efficiency, and
repeatability.
Additionally, Stanford Medicine LCGM plans to further develop a
novel technology (developed by Wilson
Wolf) that enables closed-system T cell purification to be
done directly in a G-Rex device, without the need for expensive
ancillary equipment.
ScaleReady's G-Rex Grant Program is a $20M initiative to advance the state of cell and
gene-modified cell therapy (CGT) development and manufacturing by
awarding individual Grant Awards worth up to $300,000. G-Rex Grant Recipients also gain
access to exclusive support from ScaleReady's growing consortium of
G-Rex Grant Partners who bring best-in-class tools and technologies
as well as unparalleled knowledge and expertise in the areas of
cGMP manufacturing, quality and regulatory affairs, CGT business
operations, and more.
About ScaleReady
ScaleReady provides the field of cell
and gene-modfied cell therapy (CGT) with a G-Rex centric
manufacturing platform that enables the world's most practical,
flexible, scalable, and affordable CGT drug product development and
manufacturing.
The G-Rex manufacturing platform is currently used by a rapidly
growing list of over 800 organizations and is producing drug
products for approximately 50% of CGT clinical trials as well as 4
commercially approved CGT drugs.
CGT entities relying on the breadth and scope of ScaleReady's
expertise can expect to save years of time and millions of dollars
on the path to CGT commercialization.
For more information about the ScaleReady G-Rex® Grant Program,
please contact info@scaleready.com.
About Wilson Wolf Manufacturing
Wilson Wolf (www.wilsonwolf.com) is dedicated to
simplifying cell and gene-modified cell (CGT) therapy research,
process development, and manufacturing. This is being
accomplished through its scalable G-Rex® technology, which is used
throughout the world in CGT applications ranging from basic
research to commercial drug production.
Wilson Wolf's mission is to
create hope for cancer patients, one G-Rex® device at a time.
About Bio-Techne Corporation
Bio-Techne Corporation
(NASDAQ: TECH) is a global life sciences company providing
innovative tools and bioactive reagents for the research and
clinical diagnostic communities. Bio-Techne, in partnership with
Wilson Wolf, is creating products
such as media and cytokines that are specifically tailored to
G-Rex® Bioreactors, including right-sized reagent quantities in
containers that are tailored to high throughput closed-system
manufacturing. For more information on Bio-Techne and its brands,
please visit https://www.bio-techne.com or follow the
Company on social media
at: Facebook, LinkedIn, Twitter or YouTube.
Contact: David Clair, Vice
President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
About CellReady LLC
CellReady is the world's first and
only G-Rex® centric contract development and manufacturing
organization (CDMO) specializing in G-Rex® based cell and
gene-modified cell therapy development and manufacturing. The
company offers a wide range of services to support the development
and commercialization of these therapies.
CellReady's mission is to create hope for cancer patients, one
G-Rex® process at a time.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/scaleready-announces-the-inaugural-g-rex-grant-has-been-awarded-to-stanford-medicine-laboratory-for-cell-and-gene-medicine-302228895.html
SOURCE Bio-Techne Corporation
